Jenburkt Pharmaceuticals Ltd

BSE: 524731
Jenburkt Pharmaceuticals Ltd - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1985PLC036541 Incorporated 10 June 1985 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - BSE: 524731 Public Limited Company pharma
Data last updated
Market Cap
₹408 Cr
JENBURPH · NSE
Share Price
₹935.95
+1.24% today
Revenue
₹169 Cr
FY 2025-26 · +11.2% YoY
EBITDA
₹39.79 Cr
Margin 23.6%
Net Profit
₹37.35 Cr
FY 2025-26 · +20.3% YoY
P/E (TTM)
11.7x
P/B 2.1x
ROE
18.8%
ROCE 24.6%
Debt / Equity
0.02
Interest cover 1.2x

About Jenburkt Pharmaceuticals Ltd

Data last updated:

Jenburkt Pharmaceuticals Ltd is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 June 1985 and has been in existence for over 41 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH1985PLC036541. Its GSTIN is 27AAACJ0256E1ZZ (Maharashtra). The company holds 4 GST registrations, all of them active. Its shares are listed on BSE: 524731.

The company has an authorised share capital of ₹10 Cr and a paid-up capital of ₹4.41 Cr. It was formerly known as Jen Burkt Pharmaceuticals Private Limited. It is led by directors including Ashish Uttam Bhuta (Managing Director) and Dilip Harkishandas Bhuta (Whole-Time Director).

Its last annual general meeting (AGM) was held on 18 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, India – 400058.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹168.74 Cr, a growth of 11.2% compared to the previous year. For the same year it recorded a net profit of ₹37.35 Cr (net margin 22.1%) and EBITDA of ₹39.79 Cr (EBITDA margin 23.6%). The net worth stands at ₹197.04 Cr (up 14.7% YoY). Total assets are valued at ₹202.54 Cr (up 13.4% YoY).

The company has about 765 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Jenburkt Wellness and Jenburkt. As per MCA filings, the company has open charges of ₹2.03 Cr and satisfied charges of ₹16.17 Cr on record. Court records list 32 cases involving the company, including 24 filed by the company and 6 filed against it; 6 cases are pending. The company has 31 deals on record (30 market trades, 1 buyback); the latest was in January 2023. Its 10 peer companies in the Pharma industry (Formulations, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Laboratoires Griffon Private Limited with revenue of ₹161.12 Cr. The company has 9 MSME Form 1 returns on record between 2018 and 2024, listing 20 overdue payments to 7 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jenburkt.com.

Company Details of Jenburkt Pharmaceuticals Ltd
CIN L24230MH1985PLC036541
Registration Number 036541
Incorporation Date 10 June 1985
ROC Mumbai
Listing Status Listed (BSE: 524731)
Company Status Active
Date of Last AGM 18 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Ashish Uttam Bhuta Managing Director Dilip Harkishandas Bhuta Whole-Time Director Hina Ravindra Mehta Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    jenburkt.com
  • Social Media
  • Registered Address
    Nirmala Apts 93 Jay Prakash Rd Andheri W, Mumbai, Maharashtra, India – 400058
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Jenburkt Pharmaceuticals Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Jenburkt Pharmaceuticals Ltd report

Financials, compliance, directors, charges, ownership and filings for Jenburkt Pharmaceuticals Ltd in one report.

Financials from 2015 Directors & ownership Charges & compliance

Business Activity of Jenburkt Pharmaceuticals Ltd

The main business activity of Jenburkt Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Jenburkt Pharmaceuticals Ltd FY 2025-26 filings available

Jenburkt Pharmaceuticals Ltd reported revenue of ₹168.74 Cr (up 11.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹169 Cr
+11.2% YoY
EBITDA
₹39.79 Cr
-1.5% YoY
Profit After Tax
₹37.35 Cr
+20.3% YoY
Net Worth
₹197 Cr
+14.7% YoY
Total Assets
₹203 Cr
+13.4% YoY
Total Debt
₹2.49 Cr
-36.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue169152142137124109119
Revenue growth+11.2%+6.9%+3.8%+10.3%+13.4%-8.1%-
EBITDA39.7940.3933.1230.3627.2619.8419.75
EBITDA margin+23.6%+26.6%+23.3%+22.2%+22.0%+18.2%+16.6%
Profit before tax46.5243.9335.1832.8529.8821.6421.14
Net profit37.3531.0425.9424.6022.1616.5014.87
Net profit margin+22.1%+20.5%+18.3%+18.0%+17.9%+15.1%+12.5%
EPS (₹)78.7172.6558.8655.7648.5835.9632.40
Balance sheet
Total assets20317914812812710687.71
Net worth19717214512211798.4780.00
Total debt2.493.900.002.936.755.073.44
Cash & bank53.1124.6579.1953.8149.0256.5157.69
Net working capital72.5940.1193.3668.2660.8865.8771.61
Cash flow
Cash from operations26.5227.918.1217.059.2719.4515.02
Cash from investing(19.45)(17.04)(0.58)2.62(1.20)(18.78)(2.88)
Cash from financing(8.86)(7.62)(7.08)(21.04)(5.53)(0.71)(10.83)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue35.5144.6343.0245.5635.5341.0536.8941.22
Revenue growth (YoY)-0.1%+8.7%+16.6%+10.5%+9.2%---
Other income1.514.351.822.082.061.881.581.85
Total expenses29.4934.3335.5932.4526.5730.1928.0729.79
EBITDA6.0210.307.4313.118.9610.868.8211.43
EBITDA margin+17.0%+23.1%+17.3%+28.8%+25.2%+26.5%+23.9%+27.7%
Depreciation0.640.810.830.740.720.790.780.64
Interest0.130.130.120.110.110.110.110.12
Profit before tax6.7613.718.3014.3410.1911.849.5112.52
Tax0.882.862.374.172.393.303.012.92

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue35.5144.6343.0245.5635.5341.0536.8941.22
Revenue growth (YoY)-0.1%+8.7%+16.6%+10.5%+9.2%---
Other income1.514.351.822.082.061.881.581.85
Total expenses29.4934.3335.5932.4526.5730.1928.0729.79
EBITDA6.0210.307.4313.118.9610.868.8211.43
EBITDA margin+17.0%+23.1%+17.3%+28.8%+25.2%+26.5%+23.9%+27.7%
Depreciation0.640.810.830.740.720.790.780.64
Interest0.130.130.120.110.110.110.110.12
Profit before tax6.7613.718.3014.3410.1911.849.5112.52
Tax0.882.862.374.172.393.303.012.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue169152142137124109119
Revenue growth+11.2%+6.9%+3.8%+10.3%+13.4%-8.1%-
Other income10.306.724.675.124.954.314.22
Total expenses12911110910696.7289.4599.14
Employee cost49.8845.5442.4938.8136.4932.3836.51
EBITDA39.7940.3933.1230.3627.2619.8419.75
EBITDA margin+23.6%+26.6%+23.3%+22.2%+22.0%+18.2%+16.6%
Depreciation3.112.732.342.261.902.042.30
Interest0.460.450.270.370.430.470.53
Profit before tax46.5243.9335.1832.8529.8821.6421.14
Tax11.7811.879.208.257.585.146.27
Net profit37.3531.0425.9424.6022.1616.5014.87
Net profit margin+22.1%+20.5%+18.3%+18.0%+17.9%+15.1%+12.5%
EPS (₹)78.7172.6558.8655.7648.5835.9632.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital4.414.414.414.414.594.594.59
Reserves & surplus19316714111811393.8875.41
Shareholders' funds (net worth)19717214512211798.4780.00
Secured loans0.001.980.002.445.813.710.00
Unsecured loans2.491.920.000.490.941.363.44
Total debt2.493.900.002.936.755.073.44
Total liabilities20317914812812710687.71
Assets
Gross block47.4940.3833.8633.9933.4731.9731.31
Net block19.4614.6610.3610.4511.4010.5511.73
Capital work in progress46.1240.281.240.960.210.380.12
Investments27.0220.5616.7911.187.966.754.07
Inventories13.638.888.568.349.897.5810.90
Sundry debtors24.3620.7319.4816.9615.2114.0017.83
Cash & bank balances53.1124.6579.1953.8149.0256.5157.69
Loans & advances3.992.272.501.981.781.641.55
Total current assets95.0956.5311081.0975.9079.7387.97
Total current liabilities22.5016.4216.3712.8315.0213.8616.36
Net working capital72.5940.1193.3668.2660.8865.8771.61
Total assets20317914812812710687.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash7.364.133.665.032.492.531.23
Net cash from operating activities26.5227.918.1217.059.2719.4515.02
Net cash from investing activities(19.45)(17.04)(0.58)2.62(1.20)(18.78)(2.88)
Net cash from financing activities(8.86)(7.62)(7.08)(21.04)(5.53)(0.71)(10.83)
Net change in cash(1.79)3.240.47(1.37)2.54(0.04)1.31
Closing cash53.1124.6579.1953.8149.0256.5157.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.2%+6.9%+3.8%+10.3%+13.4%-8.1%-
EBITDA growth-1.5%+22.0%+9.1%+11.4%+37.4%+0.5%-
PBT growth+5.9%+24.9%+7.1%+9.9%+38.1%+2.4%-20.6%
Net income growth+20.3%+19.7%+5.5%+11.0%+34.3%+11.0%-
Revenue CAGR (3Y)+7.3%+7.0%+9.1%+4.8%+0.4%-1.6%+4.8%
EBITDA CAGR (3Y)+9.4%+14.0%+18.6%+15.4%+3.0%-5.9%+0.1%
Profitability & leverage
Net income margin+20.6%+21.1%+18.3%+18.0%+18.0%+15.1%+12.5%
Return on capital employed+24.7%+27.2%+25.7%+26.0%+25.9%+22.8%+24.7%
Return on net worth+18.8%+20.3%+19.4%+20.5%+20.7%+18.5%+18.9%
Debt / equity0.020.010.010.040.050.050.07
Long-term debt / equity0.010.000.000.000.010.010.00
Interest cover1.251.190.881.321.702.643.04
Efficiency & per share
Fixed asset turnover3.844.094.184.053.793.454.09
Inventory turnover14.9917.4016.8015.0014.1911.8311.47
Debtors turnover7.487.547.798.508.496.875.84
EPS (₹)78.7172.6558.8655.7648.5835.9632.40
Dividend per share (₹)20.7018.0015.3014.4012.0010.208.10
Book value per share (₹)446.47389.23328.42277.32255.77214.55174.32
Want more history and ratios?
You're viewing the latest exchange-filed financials for Jenburkt Pharmaceuticals Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Peer Comparison of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Jenburkt Pharmaceuticals Ltd this company₹168.74 Cr (FY 2026)••••••••11.2%••••Mumbai, Maharashtra, India
Laboratoires Griffon Private Limited₹161.12 Cr (FY 2024)••••••••8.0%••••Kolkata, West Bengal, India
Elysium Pharmaceuticals Ltd₹159.55 Cr (FY 2024)••••••••-26.0%••••Vadodara, Gujarat, India
Gland Celsus Bio Chemicals Private Limited₹159.49 Cr (FY 2020)••••••••13377394.0%••••Hyderabad, Telangana, India
VHB Medi Sciences Limited₹159.28 Cr (FY 2025)••••••••14.0%••••Kandivlai West, Maharashtra, India
Unnati Pharmaceuticals Private Limited₹159.26 Cr (FY 2022)••••••••89.0%••••Mumbai, Maharashtra, India
Wardex Pharmaceuticals Private Limited₹158.1 Cr (FY 2025)••••••••8.0%••••Chennai, Tamil Nadu, India
Nitin Lifesciences Limited₹157.19 Cr (FY 2025)••••••••7.0%••••Paonta Sahib, Himachal Pradesh, India
Nu Sri Shyam Pharmaceuticals Private Limited₹156.54 Cr (FY 2025)••••••••15.0%••••Kolkata, West Bengal, India
New Amar Pharmaceuticals Private Limited₹156.03 Cr (FY 2024)••••••••46.0%••••Pune, Maharashtra, India
Wings Pharmaceuticals Pvt Ltd₹155.72 Cr (FY 2025)••••••••12.0%••••New Delhi, Delhi, India

Peers are the five companies nearest above and the five nearest below Jenburkt Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd is audited by D. R. Mehta & Associates for the financial year 2024.

NameStatusAppointment DateCessation Date
D. R. Mehta & AssociatesLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals has 6 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Hina Ravindra MehtaDirector28 Mar 20206 Years 6 MonthsCurrent
Dilip Harkishandas Bhuta
Also directs: Bhuta Holdings Private Limited
Whole-Time Director16 Jul 201313 Years 2 MonthsCurrent
Ashish Uttam Bhuta
Also directs: Bhuta Holdings Private Limited
Managing Director02 Jun 200719 Years 4 MonthsCurrent
Pankaj Arun Dantwala
Also directs: Clover Infoservices Private Limited, Kalzoom Technologies Private Limited, Kalzoom Management Service Technologies Private Limited
Director28 May 20242 Years 4 MonthsCurrent
Krishnan SubharamanDirector28 May 20242 Years 4 MonthsCurrent
Sumit Ajaybhai ThakkarDirector26 Jul 20233 Years 2 MonthsCurrent
View all directors

Shareholding Pattern of Jenburkt Pharmaceuticals Ltd

Shareholding for the quarter ended Sep 2026: promoters hold 46.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 53.30%.

Promoters: 46.60%DII (Domestic Institutional): 0.10%Retail & Others: 53.30%
Sep 2026
QUARTER
46.60% Promoters
0.10% DII (Domestic Institutional)
53.30% Retail & Others
Promoter holding - history
Now 46.60% · Sep 2026High 46.70% · Dec 2025Low 46.60% · Mar 2026
45%45.8%46.5%47.3%48%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 46.70%Mar 2026: 46.60%Jun 2026: 46.60%Sep 2026: 46.60%46.70%46.60%46.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters46.60%46.60%46.60%46.70%
Public53.40%53.40%53.40%53.30%

Charges & Borrowings of Jenburkt Pharmaceuticals Ltd

Open charges
₹2.03 Cr
Satisfied charges
₹16.17 Cr
Breakdown by lending institutions
Others₹2.03 Cr
Latest charge details
DateLenderAmountStatus
21 Nov 2022Others₹1 LakhOpen
21 Nov 2022Others₹2 LakhOpen
21 Nov 2022Others₹2 CrOpen
02 Dec 2022Others₹3 CrSatisfied
21 Oct 2022Others₹1.5 LakhSatisfied

Total charge records: 12 View all charges

Deals & Funding of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd has 31 deals on record (30 market trades, 1 buyback); the latest was in January 2023.

Total deals
31
Market trades
30
Buyback
1

Deals on record (5 of 31)

WhenDealAmountParties
Jan 2023Market trade₹9.17 CrBuyer: Jenburkt Pharmaceuticals Ltd
Oct 2017Market trade₹3.33 CrBuyer: Rajasthan Global Securities Private Limited
Jan 2015Market trade₹3.12 CrBuyer: an individual
Seller: Dinero Wealth Private Limited
Jul 2014Market trade₹1.62 CrBuyer: Dinero Wealth Private Limited
Jul 2014Market trade₹1.77 CrBuyer: Dinero Wealth Private Limited
Premium access

Full deal history

All 31 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd has 9 MSME Form 1 returns on record between 2018 and 2024, listing 20 overdue payments to 7 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 7)

SupplierAmount dueDue sinceReported on
Unity Foils••••••••••••
Aos Products Private Limited••••••••••••
K. Damani Hospitality Private Limited••••••••••••
an individual supplier••••••••••••
Paras Offset••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 9 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Associated Brands with Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals operates two associated brands: Jenburkt Wellness and Jenburkt. Each brand links to its own profile.

BrandDescriptionWebsite
Jenburkt
Manufacturer of pharmaceutical formulations and prescription medicationsjenburkt.com
Jenburkt Wellness
Wellness and pharmaceutical product development in India.jenburktwellness.com

Employees and EPFO Compliance at Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd has a workforce of 765 employees as of Apr 10, 2024.

Employee count
765
Active EPFO establishments
2
Employee growth
1.59%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

CIN History of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals has one previous CIN (Corporate Identification Number): U24230MH1985PLC036541. The current CIN is L24230MH1985PLC036541, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230MH1985PLC036541Current
U24230MH1985PLC036541Previous

News related to Jenburkt Pharmaceuticals Ltd

Recent Activity on Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals Ltd has 21 board changes on record since 1985: 14 appointments and 7 cessations. The latest: Arun Rangildas Raskapurwala ceased to be Director on 29 May 2024.

Charges
A charge registered on 28 Aug 2019 via Charge ID 100289026 with Others was fully satisfied on 29 Oct 2025.
AGM
Jenburkt Pharmaceuticals Ltd last Annual general meeting of members was held on 18 Jul 2025 as per latest MCA records.
Filing
Jenburkt Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
A charge registered on 21 Oct 2022 via Charge ID 100627860 with Others was fully satisfied on 22 Jan 2025.
Ceased
Arun Rangildas Raskapurwala ceased to be Director.
Ceased
Bharat Vasant Bhate ceased to be Director.
Ceased
Rameshchandra Jadavjibhai Vora ceased to be Director.
Appointed
Krishnan Subharaman was appointed as Director.
Appointed
Pankaj Arun Dantwala was appointed as Director.
Charges
A charge with Others of Rs. 2.00 Cr registered on 21 Nov 2022 with Charge ID 100652317 was modified on 19 Dec 2023.
Charges
A charge with Others of Rs. 0.02 Cr registered on 21 Oct 2022 with Charge ID 100627860 was modified on 19 Dec 2023.
Appointed
Sumit Ajaybhai Thakkar was appointed as Director.

38 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Jenburkt Pharmaceuticals Ltd

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Jenburkt Pharmaceuticals Ltd

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals has 4 GST registrations: 4 active.

Total GSTINs
4
Active
4
GSTINStateStatusRegistered on
27AAACJ0256E1ZZMaharashtraActive01 Jul 2017
24AAACJ0256E1Z5GujaratActive01 Jul 2017
06AAACJ0256E1Z3HaryanaActive21 Apr 2022
29AAACJ0256E1ZVKarnatakaActive23 May 2022
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Jenburkt Pharmaceuticals Ltd

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jenburkt Pharmaceuticals Ltd

Jenburkt Pharmaceuticals is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 June 1985 (41+ years old) and is registered under CIN L24230MH1985PLC036541. Listed on BSE: 524731.

Jenburkt Pharmaceuticals reported revenue of ₹168.74 Cr for FY 2025-26 (up 11.2% YoY) based on standalone financials.

Jenburkt Pharmaceuticals has 6 current directors:

The GSTIN of Jenburkt Pharmaceuticals is 27AAACJ0256E1ZZ, registered in Maharashtra. The company has 4 GST registrations in all, of which 4 are active. Other active GSTINs include 24AAACJ0256E1Z5 (Gujarat), 06AAACJ0256E1Z3 (Haryana), 29AAACJ0256E1ZV (Karnataka).

The CIN (Corporate Identification Number) of Jenburkt Pharmaceuticals is L24230MH1985PLC036541. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Jenburkt Pharmaceuticals is listed on BSE with code 524731.

Jenburkt Pharmaceuticals has 32 court cases on record: 24 filed by the company and 6 filed against it. 6 are pending. Most are in the high courts.

Jenburkt Pharmaceuticals was incorporated on 10 June 1985, making it 41+ years old. It is registered with the Registrar of Companies, Mumbai.

Jenburkt Pharmaceuticals has 31 deals on record (30 market trades, 1 buyback); the latest was in January 2023.

The peers of Jenburkt Pharmaceuticals by revenue are Laboratoires Griffon Private Limited, Elysium Pharmaceuticals Ltd, Gland Celsus Bio Chemicals Private Limited, VHB Medi Sciences Limited, Unnati Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).

Arun Rangildas Raskapurwala ceased to be Director on 29 May 2024. Bharat Vasant Bhate ceased to be Director on 29 May 2024. Rameshchandra Jadavjibhai Vora ceased to be Director on 29 May 2024. Jenburkt Pharmaceuticals has 21 board changes on record in total.

Jenburkt Pharmaceuticals has 9 MSME Form 1 returns on record between 2018 and 2024, listing 20 overdue payments to 7 micro and small suppliers. The latest return was filed on 03 May 2024.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available